<DOC>
	<DOCNO>NCT01237873</DOCNO>
	<brief_summary>The purpose study evaluate long-term safety tolerability combination aliskiren amlodipine give patient essential hypertension . This study conduct support registration fix combination aliskiren/amlodipine treatment hypertension Japan .</brief_summary>
	<brief_title>Long Term Safety SPA100 ( Fixed-dose Combination Aliskiren/Amlodipine ) Patients With Essential Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>Patients complete CSPA100A1301 study Patients whose blood pressure Visit 7 CSPA100A1301 study must well control Patients experienced serious adverse event consider drug relate CSPA100A1301 study Presence major protocol violation CSPA100A1301 study Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Aliskiren</keyword>
	<keyword>Amlodipine</keyword>
	<keyword>Essential hypertension</keyword>
	<keyword>Long term</keyword>
</DOC>